Cellectis Files 6-K Report, Incorporates Prior Filings
Ticker: CLLS · Form: 6-K · Filed: May 28, 2024 · CIK: 1627281
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, registration-statement
TL;DR
Cellectis filed a 6-K, basically saying 'we're still here and our old filings still count'.
AI Summary
Cellectis S.A. filed a Form 6-K on May 28, 2024, to report information as a foreign private issuer. The filing incorporates by reference previous registration statements on Form F-3 and Form S-8, indicating ongoing reporting and securities offerings. The company is based in Paris, France, and operates in the biological products sector.
Why It Matters
This filing serves as an update for investors and regulatory bodies, confirming Cellectis's ongoing compliance and the continued relevance of its previously filed registration statements for potential future securities transactions.
Risk Assessment
Risk Level: low — This is a routine administrative filing that incorporates previous disclosures and does not introduce new material risks.
Key Players & Entities
- Cellectis S.A. (company) — Registrant
- May 28, 2024 (date) — Filing Date
- Paris, France (location) — Company Headquarters
- Form 6-K (document) — Filing Type
- Form F-3 (document) — Incorporated Registration Statement
- Form S-8 (document) — Incorporated Registration Statement
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer would be required to make public pursuant to the laws of its home country or which it may otherwise make or has made public.
When was this Form 6-K filed?
This Form 6-K was filed on May 28, 2024.
What is the primary business of Cellectis S.A. according to the filing?
Cellectis S.A. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Which previous registration statements are incorporated by reference in this filing?
The filing incorporates by reference registration statements on Form F-3 (No. 333-265826) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760 and 333-273777).
Where is Cellectis S.A. headquartered?
Cellectis S.A. is headquartered at 8, rue de la Croix Jarry, 75013 Paris, France.
Filing Stats: 216 words · 1 min read · ~1 pages · Grade level 7.9 · Accepted 2024-05-28 16:16:39
Filing Documents
- clls_6-k_q1_v2.htm (6-K) — 24KB
- clls-ex99_1.htm (EX-99.1) — 2151KB
- 0000950170-24-065225.txt ( ) — 2176KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CELLECTIS S.A. (Registrant) May 28, 2024 By: /s/ André Choulika André Choulika Chief Executive Officer